In a first-of-its-kind study from researchers at the University of North Carolina (UNC) School of Medicine, a new kind of non-invasive electrical brain stimulation has been trialed in patients with major depression. The results show this new technique to be extraordinarily promising in reducing depressive symptoms, with larger trials set to explore this novel treatment in greater detail.
A Kickstarter campaign is launching on Tuesday for a drone you control with your mind.
The mind-controlled drone is the work EEGSmart, a Chinese company focused on the development of brain-machine interface (BMI) technology — and according to New Atlas writer Loz Blain, who got a chance to test the device, “It’s not perfect, but it does give a glimpse of a mind-controlled future.”
Scripps Research scientists have discovered a compound that potently and selectively kills the stem-like cells that make glioblastoma brain cancers so deadly.
In a study published this week in The Proceedings of the National Academy of Sciences, the Scripps Research scientists found that the new compound, which they dubbed RIPGBM, kills glioblastoma stem-like cells cultured from patients’ tumors with more than 40 times the potency of the standard GBM drug temozolomide. They found too that RIPGBM is highly selective, sparing other types of brain cells, and that it powerfully suppresses the growth of GBM tumors in a mouse model of the disease.
“Our discovery of this compound and the cellular pathways it affects offers a promising new strategy for treating glioblastoma,” says principal investigator Luke Lairson, PhD, an assistant professor of chemistry at Scripps Research.
Alzheimer’s disease may soon be spotted through a simple eye test, after scientists discovered tell-tale alterations in the retina and blood vessels when dementia is present.
Currently diagnosing Alzheimer’s is tricky, requiring an expensive brain scan, a risky spinal tap or in most cases a behavioural assessment by a doctor based on symptoms.
But US scientists at the Duke Eye Centre in North Carolina, wondered if changes might also be visible in the retina, which is an extension of the brain and so could offer a window into what is happening behind the skull.
A nasal spray that could alleviate symptoms of depression in just a few hours has been approved by the US Food and Drug Administration (FDA) – though the decision has attracted its share of criticism and controversy. The new drug, called esketamine, is a molecular variation of ketamine, which is already being used as an anesthetic, an antidepressant, and a party drug.
Esketamine will be sold as a spray called Spravato and is intended for patients with treatment-resistant depression, meaning they have failed to respond to at least two other types of antidepressant. Because of ketamine’s mind-altering effects and high potential for abuse, patients will be required to take Esketamine in a doctor’s office or clinic and remain under medical supervision for two hours after administration.
Most people with a diagnosis of depression are prescribed selective serotonin reuptake inhibitors (SSRIs) such as Prozac. These ensure that neurons have access to an increased amount of the neurotransmitter serotonin, which is a key emotional regulator. However, it is thought that around one-third of people with major depressive disorder (MDD) do not respond to conventional medications for the condition, which is why researchers are hunting for alternative treatments.
The APOE gene, or the “forgetting gene,” has been proven to influence Alzheimer’s risk. So a team of scientists is exploring the effect of gene therapy on people with the riskiest version of the gene.
If it works, the pay-off could be huge.
Gene therapy involves transplanting specific genetic material into human cells in order to correct genetic problems, and is typically attempted on diseases with a singular cause. Alzheimer’s doesn’t seem to have one singular cause — but since the risk of developing it is so strongly associated with the APOE gene, it’s certainly worth a try.
A new compound discovered by scientists at Scripps Research may prove to be a powerful weapon in the fight against one of the most aggressive and deadly types of cancer. Just like the cancer it fights, the compound is incredibly strong, selectively targeting the cells that allow glioblastoma multiforme (GBM) to rapidly take over the brain.
The research, which was published in a new paper in Proceedings of the National Academy of Sciences, explains how the stem-like cancer cells of GBM promote growth of the tumor while also aiding it in recurrence even after a patient has had surgery. Stopping these cells from doing their deadly deed is crucial to successful treatment, and the new compound — which the scientists have nicknamed RIPGBM — does just that.
The authors’ subsequent in-depth analysis revealed a much more complex pattern than a general inhibition of neural activity. They found that the extent of the influence of neurons on other neurons was related to how they responded to certain features of visual stimuli, such as orientation and temporal frequency. When a neuron was activated, neurons that were tuned to respond to similar features to that neuron were more strongly suppressed than were neurons with a different tu…
The contribution of a single neuron to brain function might seem negligible. But a map of the influence of single neurons reveals a complex pattern that prevents redundancy and enables clear messaging. Inhibitory and activating effects of a neuron on its neighbours.
Posted in health, neuroscience
